Login
$HUMA
$0.53 -$0.03 (4.66%) Live

$HUMA 8-K SEC Filings

Filed On Filing
10 Nov 2026 8-K: Results of Operations and Financial Condition

Humacyte Reports Third Quarter 2026 Results, Highlighted by More Than Doubling Symvess Revenue and Expanding Commercial Adoption

28 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik

12 Aug 2026 8-K: Results of Operations and Financial Condition

– Breakthrough results from V012 dialysis access Phase 3 study, where ATEV was observed to outperform AV fistula; supplemental Biologic License Application (sBLA) for dialysis access to be filed with the Food and Drug Administration (FDA...

31 Jul 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On July 31, 2026, Humacyte, Inc. (the “Company”) received a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) providing notification that, for the 30 consecutive business days ended July 30, 2026, the bid pric...

11 Jun 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

1. Introductory. Humacyte, Inc., a Delaware corporation (the “Company”), proposes to sell, pursuant to the terms of this agreement (the “Agreement”), to the several underwriters named in Schedule A hereto (the “Underwriters,” or, each, a...

10 Jun 2026 8-K: Other Events

2 Disclaimer These slides and the accompanying oral presentation contain forward-looking statements. All statements, other than statements of historical fact, included in these slides and the accompanying oral presentation are forward-lo...

09 Jun 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

Humacyte, Inc. (the “Corporation”), a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that:

05 Jun 2026 8-K: Other Events

As previously disclosed, on May 4, 2026, Humacyte, Inc. (the “Company”) received a letter from the staff of The Nasdaq Stock Market LLC (“Nasdaq”) providing notification that, for the 30 consecutive business days ended May 1, 2026, the b...

08 May 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On May 4, 2026, Humacyte, Inc. (the “Company”) received a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) providing notification that, for the 30 consecutive business days ended May 1, 2026, the bid price fo...

24 Apr 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Certain identified information has been excluded from this exhibit because such information both (i) is not material and (ii) is the type that the registrant both customarily and actually treats as private or confidential. Excluded infor...

19 Mar 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

This Securities Purchase Agreement (this “Agreement”) is dated as of March 19, 2026, between Humacyte, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its success...

19 Mar 2026 8-K: Results of Operations and Financial Condition; Other Events

2 Disclaimer These slides and the accompanying oral presentation contain forward-looking statements. All statements, other than statements of historical fact, included in these slides and the accompanying oral presentation are forward-lo...

16 Dec 2025 8-K: Entry into a Material Definitive Agreement

Humacyte, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through TD Securities (USA) LLC, as sales agent and/or principal (the “Agent”), shar...

15 Dec 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

This LOAN AND SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) dated as of December 15, 2025 (the “Closing Date”) is entered into among HUMACYTE GLOBAL, INC., a Delaware co...

15 Dec 2025 8-K: Termination of a Material Definitive Agreement

We have acted as counsel to Humacyte, Inc., a Delaware corporation (the “Company”), and are rendering this opinion in connection with the registration by the Company under the Securities Act of 1933 (the “Securities Act”), of the offer a...

26 Nov 2025 8-K: Termination of a Material Definitive Agreement

As previously disclosed, on September 1, 2022, Humacyte, Inc. (the “Company”) entered into an Open Market Sale Agreement™ (the “Agreement”) with Jefferies LLC (“Jefferies”), under which the Company may offer and sell its common stock, pa...

12 Nov 2025 8-K: Results of Operations and Financial Condition

- Total revenues of $753,000 for third quarter, and $1,571,000 for first nine months of 2025, from sales and collaborative research agreement -

07 Oct 2025 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

This Securities Purchase Agreement (this “Agreement”) is dated as of October 6, 2025, between Humacyte, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its succes...

18 Sep 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

This Amendment No. 2 to Revenue Interest Purchase Agreement (this “Amendment”), dated as of the date first set forth above, is entered into by and among Humacyte Global, Inc., a Delaware corporation (the “Company”), Humacyte, Inc., a Del...

11 Aug 2025 8-K: Results of Operations and Financial Condition

- Total revenues of $301,000 for quarter, and $818,000 for first six months of 2025, from sales and collaborative research agreement -

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support